Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 12/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25688810 | 0.89 | SLC29A1 (0.45) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL20691367 | 0.83 | SLC29A1 (0.51) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL22349184 | 0.81 | SLC29A1 (0.47) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL25688725 | 0.76 | SLC29A1 (0.39) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL20691951 | 0.74 | SLC29A1 (0.37) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL20692234 | 0.73 | CNR2 (0.32) | SLC29A1 | |
| SCHEMBL24060657 | 0.71 | SLC29A1 (0.32) | SLC29A1 | |
| SCHEMBL11934654 | 0.70 | SLC6A2 (0.33) | SLC29A1 | |
| SCHEMBL25808148 | 0.70 | SLC29A1 (0.51) | SLC29A1 | |
| SCHEMBL24680745 | 0.70 | SLC29A1 (0.32) | SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | DPYD, CD38, DUT | SLC29A1 367/4885CYP3A4 3042/4885LMNA 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.